Haber, Inc.
ph:(201) 209-9955
fx:(201) 209-9977
Best viewed with Netscape 3.0 or higher
February 20, 2001 -- COMPANY UPDATE
HABER, INC. MOVES FORWARD IN KEY AREAS
Haber, Inc. is making progress in several areas central to the Company's expansion, its ongoing product development and promotion of its technologies.
1. The 10K is complete. The 10Q's are being done now. Once they are complete, we will be current and will submit the financials to our Market Maker to be filed with the NASD for re-listing on the OTCBB. Haber Inc. cautions that we depend on parties outside of the Company for these functions.
2. We are in the final development stage for the research EMP model and the portable digital EMP 2000 instrument for qualitative and quantitative chemical and biochemical use. After manufacture of the specially designed control keypad and case, we shall have the capability to produce a fully operational product. These will satisfy both laboratory and field use needs. Also, they will serve as a basic platform for modifications intended for other uses, for example, a diagnostic instrument for the diagnostic laboratory or desk top physicians office, etc. Because the design was specifically engineered for our needs and is now available as virtually "off the shelf" components, both assembly and inventory outlays will be minimized.
The Company intends to exhibit and commercialize these units when complete. The intention is to initiate a marketing effort at various trade shows.
Key features of the new EMP units are:
Integration of multifunctional modules as a single unit to simplify user needs and functionality.
The new EMP instruments will combine the high speed resolution analysis capability of EMP with digital monitoring of the results using high resolution image capture and image analysis. This fully integrated computer-based system will allow for quantitative analysis of the analytical results, data and image storage and data transfer to compatible systems.
Built in redundant safety automation to protect the operator and the equipment.
An important reduction in size and weight with improved reliability.
Manufacturing cost optimization with high standards of precision.
Off the shelf availability for our specific design.
Applications for EMP technology include but are not limited to the following:
The Commercial Dye Industry... through the development of hundreds of proprietary protocols that are suitable for quality control of a wide variety of commercial, industrial and biomedical dyes.
The Medical/Pathology Field... by increasing the reliability of the biostains essential in pathology diagnosis. Variable dye purity can lead to staining inconsistencies. Consequently, the reliability of pathology diagnosis can be impaired and even faulty.
Forensics ... through the application of EMP technology for inks and other security needs such as documents and signature verification.
Proteinomics ... through application of EMP technology* in this developing high technology field said to be one of this century's most significant biopharmaceutical breakthroughs.
The field of proteinomics is now evolving consequent to elucidation of the genetic code of humans and other species. The genes express themselves through the agency of a myriad of proteins which provide their physiological and biological functions. EMP is very suited for the purpose of analyzing and distinguishing between different proteins. It is extremely fast and has been shown to achieve high resolution with different proteins.
*A team of researchers at two science institutes in South Korea have reported their results of protein research claiming that they have achieved a speed of greater than 1000 times that obtained with the conventional technology, electrophoresis. They used a chemical system previously reported by Mr. Haber in his EMP discovery paper at the Proceedings of the National Academy of Sciences.
The current evolving market for EMP technology includes forensics labs, biomedical research labs, dye manufacturers, and proteinomics, pharmaceutical applications, general quality control and chemistry laboratory applications.
3. The Company expects to complete its move into its new laboratories in Florida by the end of February. This facility will expedite the final development of several key applications for the EMP instruments.
4. Mr. Haber currently is submitting a research report to a leading journal in the biological stains field. This report concerns the completion of an EMP examination of all the biostain dyes normally used for diagnosis with biopsy and surgical specimens. The results were somewhat astonishing and strongly indicate a need to improve controls within purity guidelines. EMP was fast, simple to use and actually an ideal method for this.
Although there is no assurance that this scientific paper will be accepted for publication, it may be noted that the biostain dye samples were provided to Haber Inc. for this examination by officers of the Biostain Commission. Publishing such papers exposes Haber's EMP technology and its applications to the broad scientific and biomedical community. This also helps to spotlight the Company to both the financial and public arenas, lending claim to the Company's control of a proprietary and functional technology.
5. Haber's EMP technology has been featured in the past in numerous publications including "The Wall Street Journal", "BusinessWeek", "The Economist", "Chemical & Engineering News", "Chemistry in Britain", "Genetic Engineering News", and "American Biotechnology Laboratory". Scientific papers authored by Mr. Haber have been accepted for peer review and published in prestigious scientific journals such as "The Preceedings of the National Academy of Sciences" and "Biotechnic and Histochemistry".
6. Haber, Inc. continues to pursue funding for its projects and is evaluating different options at this time.
Mr. Haber and the board of directors are pleased about these developments and are committed to seeing them through as expeditiously as possible. We continue to appreciate shareholder support and confidence.
In the preceding Company Update and in general, management wishes also to inform the readers to not be lulled into the belief that our activities somehow remain independent of the limitations imposed by the financial condition of the Company. We wish to emphasize that although our expectations are high and our determination and commitment remains positive, reality governs the rate of accomplishment, and, in some instances, the feasibility of achieving our goals in a timely manner.
This Company Update contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions, and all statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, economic conditions, the impact of competition and pricing, government regulation, and other risks. All such forward-looking statements made by or on behalf of the Company are qualified. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Return to News
